Warning: The NCBI web site requires JavaScript to function. more...
Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort.
Gottenberg JE, Miceli-Richard C, Ducot B, Goupille P, Combe B, Mariette X.
Arthritis Res Ther. 2009;11(4):R114. Epub 2009 Jul 23.
Related citations
B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time.
Becker-Merok A, Nikolaisen C, Nossent HC.
Lupus. 2006;15(9):570-6.
Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis.
Bosello S, Youinou P, Daridon C, Tolusso B, Bendaoud B, Pietrapertosa D, Morelli A, Ferraccioli G.
J Rheumatol. 2008 Jul;35(7):1256-64.
Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.
Vallerskog T, Heimbürger M, Gunnarsson I, Zhou W, Wahren-Herlenius M, Trollmo C, Malmström V.
Arthritis Res Ther. 2006;8(6):R167.
Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response.
Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA, Ioan-Facsinay A, Drijfhout JW, van Tol MJ, Breedveld FC, Huizinga TW, Toes RE.
Arthritis Rheum. 2006 Dec;54(12):3799-808.
Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC.
Arthritis Rheum. 2006 Mar;54(3):723-32.
Role of anticyclic citrullinated peptide in the diagnosis of early rheumatoid factor-negative suspected rheumatoid arthritis: is it worthwhile to order the test?
Panchagnula R, Rajiv SR, Prakash J, Chandrashekara S, Suresh KP.
J Clin Rheumatol. 2006 Aug;12(4):172-5.
A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis.
Hitchon CA, Alex P, Erdile LB, Frank MB, Dozmorov I, Tang Y, Wong K, Centola M, El-Gabalawy HS.
J Rheumatol. 2004 Dec;31(12):2336-46.
Diagnostic impact of contemporary biomarker assays for rheumatoid arthritis.
Nikolaisen C, Rekvig OP, Nossent HC.
Scand J Rheumatol. 2007 Mar-Apr;36(2):97-100.
IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis.
Vis M, Bos WH, Wolbink G, Voskuyl AE, Twisk JW, Van de Stadt R, Hamann D, Dijkmans BA, Lems WF.
J Rheumatol. 2008 Mar;35(3):425-8.
Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis.
Goëb V, Dieudé P, Daveau R, Thomas-L'otellier M, Jouen F, Hau F, Boumier P, Tron F, Gilbert D, Fardellone P, Cornélis F, Le Loët X, Vittecoq O.
Rheumatology (Oxford). 2008 Aug;47(8):1208-12. Epub 2008 Jun 5.
The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis.
Liu X, Jia R, Zhao J, Li Z.
J Rheumatol. 2009 Jun;36(6):1136-42. Epub 2009 May 15.
Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, Toes RE, van der Helm-van Mil AH.
Arthritis Rheum. 2009 Aug;60(8):2232-41.
Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope.
Lakos G, Soós L, Fekete A, Szabó Z, Zeher M, Horváth IF, Dankó K, Kapitány A, Gyetvai A, Szegedi G, Szekanecz Z.
Clin Exp Rheumatol. 2008 Mar-Apr;26(2):253-60.
Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis.
Cuchacovich M, Catalan D, Wainstein E, Gatica H, Soto L, Aravena O, Pesce B, Sabugo F, Aguillón JC.
Clin Exp Rheumatol. 2008 Nov-Dec;26(6):1067-73.
Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
Mathsson L, Mullazehi M, Wick MC, Sjöberg O, van Vollenhoven R, Klareskog L, Rönnelid J.
Arthritis Rheum. 2008 Jan;58(1):36-45.
Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis.
Toubi E, Kessel A, Slobodin G, Boulman N, Pavlotzky E, Zisman D, Rozenbaum M, Rosner I.
Ann Rheum Dis. 2007 Jun;66(6):818-20. Epub 2006 Dec 5.
[The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis].
Aridoğan BC, Kaya S, Savaş S, Cetin ES, Akkuş S, Demirci M.
Mikrobiyol Bul. 2008 Oct;42(4):669-74. Turkish.
Expression of BAFF and BAFF-R in the synovial tissue of patients with rheumatoid arthritis.
Nakajima K, Itoh K, Nagatani K, Okawa-Takatsuji M, Fujii T, Kuroki H, Katsuragawa Y, Aotsuka S, Mimori A.
Scand J Rheumatol. 2007 Sep-Oct;36(5):365-72.
Antibodies to citrullinated peptides are not associated with the rate of joint destruction in patients with a well-established diagnosis of rheumatoid arthritis.
Nieto-Colonia AM, Santos WS, Keusseyan SP, Caldana W, Fernandes AR, Andrade LE.
Braz J Med Biol Res. 2008 Mar;41(3):188-92. Epub 2008 Jan 11.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on